Harvard Bioscience Inc

Name: Harvard Bioscience Inc standardized financial statements, quarterly
Creator: Listed

HBIONasdaqCIK 1123494TechnologyFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$22.7m, Q2 FY2026

Operating income−$978.0k, Q2 FY2026

Net income−$2.9m, Q2 FY2026

Harvard Bioscience Inc, income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	25.4	28.2	24.5	23.1	22.0	24.6	21.8	20.5	20.6	23.7	20.8	22.7
Cost of revenue	$m	10.6	11.8	9.7	9.9	9.2	10.5	9.6	8.9	8.6	9.6	8.5	10.1
Gross profit	$m	14.7	16.3	14.8	13.2	12.8	14.0	12.2	11.5	12.0	14.2	12.2	12.6
Research and development	$m	2.8	3.2	2.9	2.6	2.6	2.3	2.3	2.2	2.1	2.2	2.3	2.5
Operating income	$m	(0.9)	0.3	(2.3)	(2.1)	(1.9)	0.0	(49.7)	(0.8)	0.2	1.7	(1.2)	(1.0)
Interest expense	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Income tax	$m	0.7	0.7	0.2	(0.4)	0.3	0.6	(0.5)	0.0	0.1	(0.4)	0.1	0.0
Net income	$m	(1.2)	(1.8)	(4.7)	(2.9)	(4.8)	0.0	(50.3)	(2.3)	(1.2)	(2.8)	(3.4)	(2.9)
Diluted EPS	$ per share	(0.03)	not reported	(0.11)	(0.07)	(0.11)	not reported	(11.42)	(0.52)	(0.03)	not reported	(0.77)	(0.64)
Basic EPS	$ per share	(0.03)	not reported	(0.11)	(0.07)	(0.11)	not reported	(11.42)	(0.52)	(0.03)	not reported	(0.77)	(0.64)

Balance sheet

Cash and equivalents$6.5m, Q2 FY2026

Long-term debt$36.7m, Q2 FY2026

Shareholders' equity$7.4m, Q2 FY2026

Harvard Bioscience Inc, balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	5.3	4.3	4.3	4.0	4.6	4.1	5.5	7.4	6.8	8.6	7.1	6.5
Current assets	$m	50.5	49.0	48.1	46.4	46.8	45.1	44.9	45.0	43.8	48.2	47.5	46.5
Total assets	$m	140	137	133	129	131	127	79.8	80.1	78.0	80.1	77.9	76.3
Current liabilities	$m	24.2	26.5	25.7	22.6	22.8	55.0	55.6	55.2	54.4	22.0	23.9	24.8
Total liabilities	$m	65.4	64.3	64.3	61.7	65.9	63.3	65.0	64.4	63.9	66.3	67.9	68.9
Long-term debt	$m	35.3	30.7	31.9	32.0	34.3	0.0	36.4	34.9	34.0	35.9	36.2	36.7
Current portion of debt	$m	3.8	6.1	4.0	4.0	4.0	37.0	not reported	not reported	not reported	0.0	0.0	0.0
Shareholders' equity	$m	74.3	73.1	68.8	67.2	65.3	63.3	14.8	15.7	14.1	13.7	10.0	7.4

Cash flow

Operating cash flow$325.0k, Q2 FY2026

Capital expenditure$688.0k, Q2 FY2026

Harvard Bioscience Inc, cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	4,361	4,303	1,403	(846)	(842)	1,725	2,986	2,755	1,084	(96.0)	(662)	325
Capital expenditure	$k	217	830	645	818	880	301	513	89.0	207	449	426	688

Diluted shares (weighted)4.53m, Q2 FY2026

Harvard Bioscience Inc, shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	41.6	42.8	42.4	42.7	43.4	43.5	43.6	4.4	4.4	44.6	4.5	4.5

Shares outstanding: 4.55m at Aug 4, 2026, from the cover of the 10-Q filed Aug 11, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. Listed shows no prices and gives no investment advice.